ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Partial Responses To Zactima In Thyroid Cancer Trial

January 27, 2006

Watson Steps Down As Chancellor at Cold Spring Harbor Laboratory.

October 26, 2007

U.S. Radiologists Criticize Canadian Study Of Mammography Screening Showing No Benefit

November 27, 1992

In Brief: Winston Ho Heads Saint Joseph Bone Marrow Transplant Unit; Smoking Cost $452 Bil. A Year

March 16, 1990

House Subcommittee Adds $30 Billion to NCI ’79 Budget

May 12, 1978

ACS Cancer Control Research Grant Programs Available

May 5, 2000